MedTrace Logo

The Effect of Midazolam Sedation on Diagnostic Medial Branch Blocks

NCT04453449 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2022-03-07

No results posted yet for this study

Summary

This prospective observational study aims to investigate the effect of midazolam sedation on the diagnostic validity of diagnostic lumbar medial branch block in patients diagnosed with lumbar spondylosis without myelopathy.

Conditions

  • Lumbar Spine Spondylosis
  • Anxiety Generalized

Interventions

DRUG

Midazolam

Midazolam given as a sedative during diagnostic lumbar medial branch block

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2021-09-01
Completion
2021-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04453449 on ClinicalTrials.gov